Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ImmunoPET With an Anti-CD8 Imaging Agent

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04029181
Recruitment Status : Recruiting
First Posted : July 23, 2019
Last Update Posted : March 2, 2022
Sponsor:
Information provided by (Responsible Party):
Prof.dr. E.G.E. de Vries, University Medical Center Groningen

Brief Summary:
This is a single-center, single-arm, investigator sponsored trial designed to evaluate the PK of the anti-CD8 imaging agent in patients prior to and during treatment with checkpoint inhibitors.

Condition or disease Intervention/treatment Phase
Metastatic Cancer Unresectable Malignant Neoplasm Other: Anti-CD8 PET imaging agent Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: ImmunoPET Imaging With ZED88082A in Patients Before and During Treatment With 1) MPDL3280A or 2) PD-1 Antibody Plus or Minus Ipilimumab
Actual Study Start Date : February 14, 2019
Estimated Primary Completion Date : February 2023
Estimated Study Completion Date : February 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dose finding cohort
In part A of this imaging trial, a dose finding study will be performed to establish safety, to assess the appropriate protein dose for PET-scanning and to assess the appropriate PET scanning interval.
Other: Anti-CD8 PET imaging agent
An imaging agent radiolabelled with 89Zr developed for in human PET imaging of CD8

Experimental: Feasibility cohort
The purpose of part B of the study is to analyze the PK of the anti-CD8 imaging agent in patients before and during treatment with checkpoint inhibitors.
Other: Anti-CD8 PET imaging agent
An imaging agent radiolabelled with 89Zr developed for in human PET imaging of CD8




Primary Outcome Measures :
  1. Incidence of adverse events related to tracer administration as assessed by CTCAE v4.0 [ Time Frame: 2 years ]
    Safety assessment through summaries of adverse events, changes in laboratory test results (if evaluation is indicated), changes in vital signs, and exposure to ZED88082A/CED88004S. Adverse event data will be recorded and summarized according to NCI CTCAE v4.0.

  2. Appropriate dosing of anti-CD8 imaging agent and PET imaging time points [ Time Frame: 2 years ]
    Appropriate dosing and imaging time points of the anti-CD8 imaging agent will be determined based on measurements of standardized uptake value (SUV) of defined volumes of interest (VOIs) on the immunoPET scan images

  3. Pharmacokinetics (PK) of anti-CD8 imaging agent [ Time Frame: 2 years ]
    Description of PK of the anti-CD8 imaging agent by measuring standardized uptake value (SUV) on PET scans performed 0, 2, 4 and/or 7 days after tracer injection before and during MPDL3280A or PD-1 antibody immune checkpoint inhibitor plus or minus ipilimumab treatment.

  4. Immunogenic potential of the anti-CD8 imaging agent by measuring incidence of anti-drug antibodies [ Time Frame: 2 years ]
    Assessment of the immunogenic potential of the anti-CD8 imaging agent by measuring incidence of anti-drug antibodies during the study relative to the prevalence of ADAs at baseline and assessing their relationship to other outcomes measured.


Secondary Outcome Measures :
  1. Heterogeneity of tumor uptake of the anti-CD8 imaging agent [ Time Frame: 2 years ]
    Heterogeneity of imaging tracer uptake will be evaluated by measuring standardized uptake value (SUV) in defined volumes of interest (VOIs) of tumor lesions on the immunoPETscan images

  2. Correlation of normal organ uptake of the anti-CD8 imaging agent to (serious) adverse events (possibly) related to immune checkpoint inhibitor treatment [ Time Frame: 2 years ]
    Normal organ uptake of the anti-CD8 imaging agent as measured by SUVs on PET scan images will be analyzed on correlation to (serious) adverse events (possibly) related to ICI treatment, defined as all (S)AEs which are assessed as "possibly", "probably" or "definitely" related to ICI treatment.

  3. Correlation of tumor uptake of the anti-CD8 imaging agent and immune cell CD8 expression [ Time Frame: 2 years ]
    Results of immunohistochemical scoring of tumor and immune cell CD8 and other markers of lymphocytic infiltration in fresh biopsies will be described as a semi-quantitative score using the percentage of positive cells (continuous variable), intensity and pattern of staining (discrete variable). These IHC results will be compared with imaging tracer standardized uptake value (SUV) in defined volumes of interest (VOIs) of tumor lesions on the immunoPETscan images. Results of autoradiography will be described by measuring standardized uptake value (SUV) on the biopsy slides.

  4. Correlation of anti-CD8 imaging agent normal tissue kinetics with blood kinetics [ Time Frame: 2 years ]
    PK parameters will be derived from anti-CD8 imaging agent serum concentrations and will be summarized using descriptive statistics including but not limited to the number of patients, mean, standard deviation, median, minimum and maximum.

  5. Dosimetry [ Time Frame: 2 years ]
    Assessment of dosimetry will be performed by calculations of radioactivity in Bq or mSv of anti-CD8 imaging agent concentration in tumor target tissue, blood and other organs of interest with regards to injected dose (ID), derived from measurements of standardized uptake value (SUV) on immunoPET images and direct analysis of blood 89Zr-activity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects with histologically confirmed locally advanced or metastatic cancer for the following tumor types

    • Cancer types other than melanoma; subjects meeting the eligibility criteria as formulated in the MPDL3280A treatment study protocol (MPDL3280A-treatment-IST-UMCG) are eligible for part A or part B1.
    • Melanoma; subjects eligible to receive standard of care anti-PD1 therapy plus or minus ipilimumab, are eligible for part B2.
  2. Tumor lesion(s) of which a histological biopsy can safely be obtained according to standard clinical care procedures.
  3. Measurable disease, as defined by standard RECIST v1.1. Previously irradiated lesions should not be counted as target lesions.
  4. Signed informed consent.
  5. Age ≥18 at the time of signing informed consent.
  6. Life expectancy ≥12 weeks.
  7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  8. Ability to comply with the protocol.
  9. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly).

Exclusion Criteria:

  1. Potential subjects with cancer other than melanoma will be excluded from participation in this study if they meet exclusion criteria formulated in the MPDL3280A treatment study protocol (MPDL3280A-treatment-IST-UMCG).
  2. Signs or symptoms of infection within 2 weeks prior to anti-CD8 imaging agent injection.
  3. Prior immune checkpoint inhibitor treatment, including but not limited to anti-PD1 and anti-PD-L1 therapeutic antibodies.
  4. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  5. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the anti-CD8 imaging agent, or that may affect the interpretation of the results or render the patient at high risk from complications.
  6. Pregnant or lactating women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04029181


Contacts
Layout table for location contacts
Contact: E. G.E. de Vries, MD, PhD +31 50 361 2821 e.g.e.de.vries@umcg.nl

Locations
Layout table for location information
Netherlands
University Medical Center Groningen Recruiting
Groningen, Netherlands
Contact: E. G.E. de Vries, MD, PHD    +31 50 361 2821    e.g.e.de.vries@umcg.nl   
Principal Investigator: E. G.E. de Vries, MD, PhD         
Sponsors and Collaborators
University Medical Center Groningen
Investigators
Layout table for investigator information
Principal Investigator: E. G.E. de Vries, MD, PhD University Medical Center Groningen
Layout table for additonal information
Responsible Party: Prof.dr. E.G.E. de Vries, Principal investigator, University Medical Center Groningen
ClinicalTrials.gov Identifier: NCT04029181    
Other Study ID Numbers: 201700848
First Posted: July 23, 2019    Key Record Dates
Last Update Posted: March 2, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms